![In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy](https://www.science.org/cms/10.1126/sciadv.abj6901/asset/24c8fa7f-402b-4140-812b-b6eaff882322/assets/images/large/sciadv.abj6901-f3.jpg)
In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy
![In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy](https://www.science.org/cms/10.1126/sciadv.abj6901/asset/8e104bb3-894a-42c1-bbc4-78a6de16119a/assets/images/large/sciadv.abj6901-f4.jpg)
In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy
![In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy](https://www.science.org/cms/10.1126/sciadv.abj6901/asset/57664d23-e111-4a72-93e3-5551fb473145/assets/images/large/sciadv.abj6901-f1.jpg)
In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy
![In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy](https://www.science.org/cms/10.1126/sciadv.abj6901/asset/8be00a14-e25e-4252-95d9-9a4c144ddfab/assets/images/large/sciadv.abj6901-f2.jpg)